Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus DIFLUCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus DIFLUCAN.
AMPHOTEC vs DIFLUCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Category C
Category C
Antifungal
Antifungal